Minimal Residual Disease Testing for the Early Detection of Cancer Recurrence in Resectable Stage II-IV Colorectal Cancer Patients
Public ClinicalTrials.gov record NCT07125729. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
ctDNA Testing in Resectable Stage II-IV Colorectal Cancer Patients: A Head-to-Head Performance Comparison
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This clinical trial compares minimal residual disease (MRD) testing with the Haystack blood test (assay) to the Signatera® assay for the early detection of the cancer returning (cancer recurrence) in patients with stage II-IV colorectal cancer (CRC) that can be removed by surgery (resectable). MRD testing looks for evidence of remaining tumor following treatment that is only apparent using highly sensitive techniques. There are few effective tools available outside of imaging to identify CRC patients with MRD who may be at the highest risk for cancer recurrence after surgery. Early detection of CRC recurrence after surgery is important, as it may increase the chance of curative (ability to cure) outcomes for patients with cancer recurrence. Currently, the Signatera assay is used to monitor whether CRC recurs after surgery, however it is not a very sensitive test. Early work with the Haystack assay suggests it may be more sensitive than the Signatera assay, which may be more effective for the early detection of cancer recurrence in patients with resectable stage II-IV CRC.
Study identification
- NCT ID
- NCT07125729
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 150 participants
Conditions and interventions
Conditions
Interventions
- Biospecimen Collection Procedure
- cfDNA or ctDNA Measurement Other
- Electronic Health Record Review Other
Procedure · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 28, 2025
- Primary completion
- Jan 8, 2028
- Completion
- Jan 8, 2028
- Last update posted
- Aug 11, 2026
2025 – 2028
United States locations
- U.S. sites
- 13
- U.S. states
- 4
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| CTCA at Western Regional Medical Center | Goodyear | Arizona | 85338 | Recruiting |
| City of Hope Corona | Corona | California | 92882 | Recruiting |
| City of Hope Comprehensive Cancer Center | Duarte | California | 91010 | Recruiting |
| City of Hope Seacliff | Huntington Beach | California | 92648 | Recruiting |
| City of Hope at Irvine Lennar | Irvine | California | 92618 | Recruiting |
| City of Hope Antelope Valley | Lancaster | California | 93534 | Recruiting |
| City of Hope at Long Beach Elm | Long Beach | California | 90813 | Recruiting |
| City of Hope at Newport Beach Fashion Island | Newport Beach | California | 92660 | Recruiting |
| City of Hope South Pasadena | South Pasadena | California | 91030 | Recruiting |
| City of Hope South Bay | Torrance | California | 90503 | Recruiting |
| City of Hope Upland | Upland | California | 91786 | Recruiting |
| City of Hope Atlanta Cancer Center | Newnan | Georgia | 30265 | Recruiting |
| City of Hope at Chicago | Zion | Illinois | 60099 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07125729, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 11, 2026 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07125729 live on ClinicalTrials.gov.